GEMS 2027 PhD: Co-designing Community Antimicrobial Stewardship Through One Health

GEMS 2027 PhD: Co-designing Community Antimicrobial Stewardship Through One Health

Executive Verdict

Recommendation label: Strong but verify fit. This is a strong opportunity for a doctoral applicant interested in community antimicrobial stewardship (AMS), pharmacy practice, implementation science, public health and One Health. The main strengths are the official Monash GEMS funding package, the strong Monash pharmacy/pharmacology signal, and a project design that fits current WHO and Malaysia AMR priorities around people-centred, primary-care and community engagement.

The main caution is that the public evidence is not yet detailed enough on field sites, language requirements, partner organisations, ethics status, pilot outcomes or day-to-day supervision. The project is also more behavioural and implementation-oriented than a purely laboratory AMR project. Applicants comparing this opportunity should verify these uncertainties before investing in a full proposal.

The GEMS scholarship rules, checked on 9 September 2026, list 25 January 2027. The project record captured on 6 November lists 31 January 2027. The saved evidence does not establish whether these are separate scholarship and project deadlines or a listing discrepancy. To protect scholarship eligibility, plan around the earlier date and ask Monash which applies. The same GEMS scholarship rules also state that enrolment must occur by 31 December 2027. This is a general scholarship rule; the saved material does not establish whether it applies to this topic, so confirm with Monash. It is an enrolment deadline, separate from the application deadlines above. No closing hour or current application availability is confirmed. Project-specific resources, access, supervision and mobility arrangements also require confirmation. GEMS scholarship rules

School, Programme, and Location Signal

The institutional signal is strong. Monash reports that the 2026 QS World University Rankings by Subject placed Monash second globally for Pharmacy and Pharmacology and first in Australia for that subject area. The QS subject-ranking page also lists Monash in second place globally for Pharmacy and Pharmacology. Monash Malaysia's own ranking page lists broader university signals including QS 2027 world #31, THE 2026 world #58 and ARWU 2025 world #76. THE's Monash profile similarly places Monash at world #58 for 2026 and #27 for Clinical and Health.

For this specific project, the relevant school environment is Monash University Malaysia's School of Pharmacy. The School describes itself as an extension of Monash's Australian Faculty of Pharmacy and Pharmaceutical Sciences and presents graduate research pathways including PhD study. Its research themes include pharmacy practice and pharmacy education, global health and health policy, drug delivery and nanomedicine, and other health-related areas. The Pharmacy Practice discipline is particularly relevant because it focuses on safe, effective and equitable use of medicines across communities, hospitals and healthcare systems, with work in public health, health services research, global health and integrated care.

The project therefore has a stronger environment signal than a generic health-project listing: it sits at the intersection of a globally ranked pharmacy school, a Malaysia health-system setting, and an AMR research ecosystem. The caveat is that rankings and school pages are not project-level proof. The exact community partners, fieldwork resources and supervision mechanics still need confirmation.

Sources: Monash Pharmacy about, School research themes, Pharmacy Practice discipline, Monash postgraduate pharmacy research, Monash QS 2026 Pharmacy ranking news, QS Pharmacy and Pharmacology 2026, Monash Malaysia rankings, THE Monash profile.

Supervisor and Lab Assessment

Supervisor Research Directions

The official Monash project page names the supervisory team as Assoc. Prof. Alice Chuah, Dr Patrick Tan Hock Siew, Dr Saw Pui San and Assoc. Prof. Daniel Malone. The team looks deliberately cross-disciplinary.

Alice Chuah is an Associate Professor in the Malaysia School of Pharmacy and is listed as accepting PhD students. Her profile centres on advanced drug delivery systems, nanoparticles, hydrogels, polymeric membranes, natural bioactives, wound and dermal delivery, and public-health-adjacent work such as sustainable water filtration and rural communities. This is useful for the wider closed-loop infection/AMR cluster, although her public profile is not primarily behavioural AMS.

Patrick Tan has the clearest direct AMR alignment. His Monash profile lists antimicrobial resistance, molecular microbiology, aptamer technology, genomics and transcriptomics. The Monash Centre to Impact AMR profile links him to AMR therapeutic solutions, AMR evolution and protective microbiomes, multiomics, AMR transmission including wastewater, aptamer diagnostics/inhibitors and phage biology.

Saw Pui San provides the strongest pharmacy-practice and qualitative/public-health fit. Her profile lists public health, clinical/pharmacy practice, qualitative research, social administrative research, planetary health and wellbeing. The Pharmacy Practice discipline page also places her in an environment focused on safe medicine use, healthcare systems and public health.

Daniel Malone is based in Pharmacy and Pharmaceutical Sciences Education and brings Australian pharmacy education and accreditation context. His public profile is less directly AMR-oriented, so the value of his supervision likely depends on the Australia mobility plan and education/behavioural-intervention aspects.

Recent Important Publications

Recent publication evidence supports the team's breadth, but not every paper is directly about community AMS.

Alice Chuah co-authored a 2023 review on chitosan-based drug delivery systems for atopic dermatitis. The relevance is drug-delivery and antimicrobial/anti-inflammatory biomaterials, which supports her broader infection and wound-health credibility but is not a direct community AMS paper.

Patrick Tan co-authored a 2025 FEMS Microbiology Letters paper on the antibiofilm activity of Clitoria ternatea anthocyanin fraction against oral biofilm-forming bacteria. This supports recent AMR-adjacent microbiology and biofilm-control activity.

Saw Pui San co-authored a 2025 qualitative study of Malaysian community pharmacists' views on mental-health screening and management. Although the topic is not antibiotics, the setting and method are highly relevant: semi-structured interviews, community pharmacists, perceived roles, training needs, resource gaps and implementation barriers.

Lab, Resources, and Collaboration Environment

The Monash Centre to Impact AMR is a useful surrounding ecosystem. Its official pages describe a large interdisciplinary team across microbiology, engineering, chemistry, education, clinical research, anthropology and social sciences, and AMR themes including therapeutic solutions, AMR evolution, transmission/control, AI solutions and public AMR prevention/care. For this project, the most relevant signal is not only laboratory capability but the availability of social-science and implementation-oriented AMR expertise. Patrick Tan is explicitly listed within relevant AMR Centre themes.

The major unknown is whether this exact project has secured community partners, field sites, ethics groundwork, transcription/translation resources and a named Australia mobility host plan. These should be treated as verification questions, not assumed facts.

Sources: Official project page, Alice Chuah profile, Patrick Tan profile, Patrick Tan AMR Centre profile, Saw Pui San profile, Daniel Malone profile, Centre to Impact AMR about, AMR Centre impact themes, Chuah 2023 paper, Tan 2025 paper, Saw 2025 paper.

Research Direction and Field Outlook

Field Momentum

The topic is well aligned with current AMR policy and research momentum. WHO's 2026 AMR fact sheet describes AMR as a major global health threat, driven in part by misuse and overuse of antimicrobials and by gaps in diagnostics, medicines, WASH and health-system capacity. WHO's people-centred AMR package frames AMR action around infection prevention, access to essential services, timely diagnosis, appropriate treatment, governance/education and surveillance/research. WHO's 2025 primary-health-care policy brief further supports mainstreaming AMR interventions into primary care and community engagement.

Malaysia-specific evidence also supports the project's direction. The WHO library records Malaysia's MyAP-AMR 2022-2026, and the Malaysia One Health AMR portal lists the national action plan, integrated surveillance manual and reports across AMR surveillance and antimicrobial utilisation/consumption. A peer-reviewed Malaysian One Health perspective argues that attitudes, beliefs, social behaviour and LMIC community/farming contexts remain underexplored in Malaysia. That is directly relevant to a project that begins with interviews, focus groups and stakeholder mapping.

Potential Research Angles

The strongest research angles are practical and implementation-focused:

1. Map community decision pathways for antimicrobial use: who advises, who buys, who dispenses, who influences adherence, and where misinformation or access constraints enter.
2. Identify barriers and facilitators for pharmacist-led counselling or referral pathways in Malaysian community settings.
3. Use participatory co-design to create education tools, counselling scripts, decision-support materials or referral workflows that are culturally and operationally realistic.
4. Pilot-test feasibility, acceptability and early implementation outcomes rather than trying to prove full clinical effectiveness within one PhD.
5. Connect human-health behaviour to One Health messages without letting the thesis become too broad across human, animal and environmental sectors.

The design has a real scope-management challenge. The public project description includes community education tools, pharmacist-led counselling, referral pathways, decision-support materials and scale-up evidence. A doctoral project will need a narrow setting, stakeholder group and outcome framework.

Career and Market Outlook

Career relevance is credible but should be framed realistically. The project could support pathways in pharmacy-practice research, public health, AMS implementation, health services research, One Health programme evaluation, policy research, NGO/global-health work, pharmaceutical services, or academia. WHO's 2026 Global Action Plan adoption for AMR 2026-2036 suggests sustained policy priority. WHO's 2026 health workforce report highlights ongoing workforce planning needs, and Jobs and Skills Australia reports pharmacist employment and growth data for Australia. These are useful market indicators, especially because the GEMS programme includes Australia mobility, but they are not guarantees of Malaysian, Chinese or Australian employment.

Applicants needing pharmacist registration should treat this as separate from doctoral admission. A PhD in this area can strengthen research and policy credentials; it does not by itself solve country-specific clinical registration requirements.

Sources: WHO AMR fact sheet, WHO people-centred AMR package, WHO PHC-oriented AMR policy brief, Malaysia MyAP-AMR 2022-2026, Malaysia One Health AMR publications, Malaysia AMR human-health reports, Malaysian One Health AMR perspective, Systems thinking for AMS in primary care, Malaysian pharmacists AMS qualitative study, 2026 Malaysian pharmacists AMS barriers study, Jobs and Skills Australia Pharmacists profile, WHO health workforce 2026, WHO updated GAP-AMR 2026-2036.

Funding, Application, and Living Cost

The saved GEMS rules describe 15 scholarships each year, each with 42 months of funding. It lists a Malaysia stipend of RM2,950/month for 33-36 months, an Australia mobility stipend of RM8,500/month for up to nine months, RM2,950/month for Indonesia or India mobility, a RM9,000 grant for visa/insurance/travel subsidy, and a 100% tuition-fee waiver up to four years. The official page also states Malaysian and international students are eligible.

Eligibility is selective. GEMS requires a minimum academic qualification of First Class Honours (H1) or H1-equivalence recognised by Monash Malaysia. Monash graduate research admission criteria also require evidence of independent research capacity and relevant research training, such as a four-year bachelor with thesis/project at 2A-equivalent level, a relevant research master's, or equivalent qualifications/experience. For Pharmacy and Pharmaceutical Sciences graduate research English requirements, Monash lists IELTS 6.5 overall with no band below 6.0, with TOEFL, PTE and Cambridge alternatives.

For Chinese applicants, the public evidence supports eligibility as international applicants, but not automatic competitiveness. Key checks are Chinese transcript conversion to H1/H1E, English evidence validity, whether documents require certified translation, and student-pass timing. Monash Malaysia states international full-time students must accept the offer and apply for a student pass before coming to Malaysia, and research students should pay attention to the minimum processing time.

Living cost appears manageable but not risk-free. Monash Malaysia's cost guide lists Monash-run residence monthly rent at RM330-1500, street-stall food RM6-12, groceries RM30-80, and other monthly costs from RM400. A modest single-student budget can fit the RM2,950 monthly Malaysia stipend, but private accommodation, dependants, fieldwork travel, transcription/translation, conference costs or personal travel can materially change this.

Sources: GEMS scholarship page, Monash graduate research admission criteria, Monash graduate research English requirements, Monash Malaysia student pass, Monash Malaysia cost of living, Monash Malaysia accommodation.

Applicant Fit and Preparation

Best suited for

This project is best suited for applicants who can bridge health, behaviour and systems. Strong backgrounds include pharmacy, public health, health services research, implementation science, epidemiology, behavioural science, medical sociology/anthropology, microbiology with translation interest, or broader One Health training. Pharmacy applicants have obvious domain fit, but the project does not look restricted to one discipline if the applicant can show the right research capacity.

Applicants with community, hospital, pharmacy, public-health or stakeholder-facing experience will have a stronger evidence story. Prior qualitative interviewing, focus groups, survey design, thematic analysis, NVivo or equivalent coding, ethics drafting and intervention co-design would be particularly useful.

May need caution if

Caution is warranted if the applicant expects a primarily wet-lab project, wants antibiotic discovery rather than AMS implementation, lacks independent research evidence, or is uncomfortable with fieldwork and community stakeholders. Applicants without strong English writing, proposal-writing and methodological preparation may struggle because GEMS requires a research proposal and the project involves behavioural and implementation design.

Chinese applicants should verify H1/H1E equivalence early. They should also ask whether Malay-language data collection is expected, whether interpreters or bilingual research assistants are available, and whether community-facing work can be done primarily in English or Mandarin in any selected sites.

Skills and evidence to strengthen

The most relevant preparation areas are:

1. AMR/AMS policy literacy, especially WHO people-centred AMR and Malaysia MyAP-AMR.
2. Qualitative methods: interview guide design, focus groups, sampling, reflexivity and thematic analysis.
3. Stakeholder mapping and participatory co-design.
4. Implementation science: feasibility, acceptability, adoption, fidelity and early outcome metrics.
5. Community pharmacy and primary-care workflow understanding.
6. Ethics and data-protection readiness for health and community research.
7. A focused GEMS proposal that narrows the population, setting, intervention type and pilot evaluation plan.

Sources: Official project page, GEMS scholarship page, Pharmacy Practice discipline, Monash graduate research admission criteria, Monash graduate research English requirements, WHO people-centred AMR package, WHO PHC-oriented AMR policy brief, Saw 2025 community pharmacist paper, Malaysian pharmacist AMS qualitative study.

Risks and Questions to Verify

High-priority questions

1. Does the 25 January scholarship date or 31 January project-record date apply, and what local closing time does Monash use? Until confirmed, can the application be completed by 25 January?
2. Which communities, pharmacies, clinics, public-health agencies, animal/environment partners or other One Health stakeholders are already available for recruitment?
3. Will interviews, focus groups or co-design workshops require Malay or other local-language capability?
4. What are the expected sample size, ethics pathway, recruitment timeline and pilot evaluation metrics?
5. How will Alice Chuah, Patrick Tan, Saw Pui San and Daniel Malone divide supervision responsibilities?
6. Which Australia campus, group or supervisor will host the mobility period, and how will it contribute to the thesis?
7. Does the funding cover fieldwork, transcription, translation, conference attendance or open-access publication charges?

Medium-priority questions

1. Which implementation-science framework does the team expect the student to use, if any?
2. Is the intervention expected to be pharmacist-led, community-led, school-based, clinic-linked or multi-sectoral?
3. Are there existing baseline data on community antimicrobial beliefs or use patterns in the intended setting?
4. How much academic-support or research-support duty is normally required under GEMS in the School of Pharmacy?
5. How does Monash Malaysia assess H1/H1E equivalence for Chinese degrees and grading scales?
6. What prior publications, field experience or methods training would make a candidate more competitive for this topic?

Evidence and Sources

• Official project page: source
• GEMS scholarship page: source
• School of Pharmacy: source
• Pharmacy research themes: source
• Pharmacy Practice discipline: source
• Postgraduate pharmacy research: source
• Alice Chuah profile: source
• Patrick Tan profile: source
• Patrick Tan AMR Centre profile: source
• Saw Pui San profile: source
• Daniel Malone profile: source
• Centre to Impact AMR about: source
• AMR Centre impact themes: source
• Monash QS 2026 Pharmacy ranking news: source
• QS Pharmacy and Pharmacology 2026: source
• Monash Malaysia rankings: source
• THE Monash profile: source
• Monash Malaysia cost of living: source
• Monash Malaysia accommodation: source
• Monash graduate research admission criteria: source
• Monash graduate research English requirements: source
• Monash Malaysia student pass: source
• Malaysia MyAP-AMR 2022-2026: source
• Malaysia One Health AMR publications: source
• Malaysia AMR human-health reports: source
• WHO AMR fact sheet: source
• WHO people-centred AMR package: source
• WHO PHC-oriented AMR policy brief: source
• Malaysian One Health AMR perspective: source
• Systems thinking for AMS in primary care: source
• Chuah 2023 paper: source
• Tan 2025 paper: source
• Saw 2025 paper: source
• Malaysian pharmacists AMS qualitative study: source
• 2026 Malaysian pharmacists AMS barriers study: source
• Jobs and Skills Australia pharmacist profile: source
• WHO health workforce 2026: source
• WHO updated GAP-AMR 2026-2036: source